APOC1 Antibody

Size

100ul

Clone Number

Aliases

Apolipoprotein C-I (Apo-CI) (ApoC-I) (Apolipoprotein C1) [Cleaved into: Truncated apolipoprotein C-I], APOC1

Immunogen Species

Homo sapiens (Human)

UniProt ID

P02654

Immunogen

Recombinant Human Apolipoprotein C-I protein (35-48aa)

Raised in

Rabbit

Species Reactivity

Human

Tested Applications

ELISA, IHC; Recommended dilution: IHC:1:100-1:500

Background

Inhibitor of lipoprotein binding to the low density lipoprotein (LDL) receptor, LDL receptor-related protein, and very low density lipoprotein (VLDL) receptor. Associates with high density lipoproteins (HDL) and the triacylglycerol-rich lipoproteins in the plasma and makes up about 10% of the protein of the VLDL and 2% of that of HDL. Appears to interfere directly with fatty acid uptake and is also the major plasma inhibitor of cholesteryl ester transfer protein (CETP). Binds free fatty acids and reduces their intracellular esterification. Modulates the interaction of APOE with beta-migrating VLDL and inhibits binding of beta-VLDL to the LDL receptor-related protein.

Clonality

Polyclonal

Isotype

IgG

Purification Method

>95%, Protein G purified

Conjugate

Non-conjugated

Buffer

Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, pH 7.4

Form

Liquid

Stroage

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.

Target Names

APOC1

Research Areas

Cardiovascular